120 related articles for article (PubMed ID: 37961510)
1. Clinical validity and utility of circulating tumor DNA (ctDNA) testing in advanced non-small cell lung cancer (aNSCLC): a systematic literature review and meta-analysis.
Chen C; Douglas MP; Ragavan MV; Phillips KA; Jansen JP
medRxiv; 2023 Oct; ():. PubMed ID: 37961510
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Sebastião MM; Ho RS; de Carvalho JPV; Nussbaum M
J Health Econ Outcomes Res; 2020; 7(2):158-163. PubMed ID: 33043062
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumour DNA (ctDNA) as a Predictor of Clinical Outcome in Non-Small Cell Lung Cancer Undergoing Targeted Therapies: A Systematic Review and Meta-Analysis.
Zaman FY; Subramaniam A; Afroz A; Samoon Z; Gough D; Arulananda S; Alamgeer M
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173891
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
Fan G; Zhang K; Ding J; Li J
Oncotarget; 2017 May; 8(20):33922-33932. PubMed ID: 28430611
[TBL] [Abstract][Full Text] [Related]
5. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
6. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
7. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
[TBL] [Abstract][Full Text] [Related]
8. Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patients.
Kim S; Kim S; Kim SH; Jung EH; Suh KJ; Kim YJ; Kwon NJ; Kim H; Chung JH; Lee JS
Transl Lung Cancer Res; 2023 Jun; 12(6):1185-1196. PubMed ID: 37425402
[TBL] [Abstract][Full Text] [Related]
9. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea.
Ahn BC; Lee S; Lee J; Lee JB; Hong MH; Lim SM; Jain S; Olsen S; Cho BC
Cancer Treat Res Commun; 2023; 36():100715. PubMed ID: 37307681
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
Julian C; Pal N; Gershon A; Evangelista M; Purkey H; Lambert P; Shi Z; Zhang Q
BMC Cancer; 2023 Apr; 23(1):352. PubMed ID: 37069542
[TBL] [Abstract][Full Text] [Related]
13. An update of clinical value of circulating tumor DNA in esophageal cancer: a systematic review and meta-analysis.
Zhang Y; Du H; Wang N; Wang L; Huang Y
BMC Cancer; 2024 Jan; 24(1):129. PubMed ID: 38267901
[TBL] [Abstract][Full Text] [Related]
14. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
[TBL] [Abstract][Full Text] [Related]
15. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).
Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V
Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer.
Lyu M; Zhou J; Ning K; Ying B
Onco Targets Ther; 2019; 12():2539-2552. PubMed ID: 31040697
[TBL] [Abstract][Full Text] [Related]
17. Exploring Circulating Tumor DNA (CtDNA) and Its Role in Early Detection of Cancer: A Systematic Review.
Bittla P; Kaur S; Sojitra V; Zahra A; Hutchinson J; Folawemi O; Khan S
Cureus; 2023 Sep; 15(9):e45784. PubMed ID: 37745752
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of postoperative ctDNA detection in patients with early non-small cell lung cancer: a systematic review and meta-analysis.
Guo K; Lu J; Lou Y; Zheng S
Ther Adv Med Oncol; 2023; 15():17588359231177008. PubMed ID: 37256023
[TBL] [Abstract][Full Text] [Related]
19. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
20. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
